Evidence map›Paper›PMID 34154709›Full record

ArticleKidney international2021

APOL1-associated kidney disease in northern Nigerians with treated HIV infection.

Opeyemi A Olabisi, Barry I Freedman

Expression of concernOpen access · greenAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Opeyemi A OlabisiDepartment of Medicine, Division of Nephrology and Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Barry I FreedmanDepartment of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. Electronic address: bfreedma@wakehealth.edu.
Duke University · USWake Forest University · US

Funding

JAK-STAT Inhibition to Reduce Racial Disparities in Kidney DiseaseR01MD016401 · NIMHD · DUKE UNIVERSITY · PI OLABISI, OPEYEMI AYODEJI · 2021 to 2025
$3.5M
A Human Stem Cell-Derived Podocyte Model for APOL1 NephropathyDP2DK124891 · NIDDK · DUKE UNIVERSITY · PI OLABISI, OPEYEMI AYODEJI · 2019 to 2019
$2.4M
NIDDK NIH HHS DP2 DK124891NIMHD NIH HHS R01 MD016401
6 · The paper itself

Abstract

Apolipoprotein L1 (APOL1) high-risk genotypes strongly associate with HIV-associated nephropathy, and antiretroviral therapy reduces the incidence of HIV-associated nephropathy and progression to end-stage kidney disease. Wudil et al. report cross-sectional APOL1 associations with proteinuria and estimated glomerular filtration rate in a northern Nigerian sample with HIV infection on antiretroviral therapy. Multiple ethnic groups with different APOL1 risk variant frequencies were included. Overall, APOL1 was associated with proteinuric chronic kidney disease; however, relationships with underlying causes of nephropathy and progression rates require further study.

Indexed as

Apolipoprotein L1HIV InfectionsAdultApolipoproteinsCross-Sectional StudiesGenotypeHumansKidneyLipoproteins, HDLNigeriaPhenotypeAPOL1 protein, humanApolipoprotein L1ApolipoproteinsLipoproteins, HDL

Identifiers

PMID34154709
PMCPMC9827565
OpenAlexW3176007143

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.